

Chiesi Total CareSM Fact Sheet

A single call to your dedicated Chiesi Total Care Team is all it takes—we will guide you through the process of getting a patient started on Lamzede[®] (velmanase alfa-tycv) therapy.

Insurance eligibility—Chiesi Total Care assists you and your patients with:



Commercial insurance

If your patients have private insurance through their job or their own business



Government insurance

If your patients have Medicare, Medicaid, Veterans Affairs healthcare, or other government insurance



No insurance

If your patients have no insurance, they may be eligible for financial assistance

Copay Assistance

With the Lamzede Copay Programs, eligible patients may pay as little as \$0 for their medication and/or infusions.*

To be eligible for these programs:

- Your patient must be enrolled in Chiesi Total Care. (Enrollment and Authorization Form will be mailed to your patient's home)
- Your patient must have commercial insurance and a valid prescription for a US FDA-approved indication for Lamzede
- Your patient must be a resident of the United States or one of its territories

Please refer to the accompanying full [Terms and Conditions](#) for additional eligibility requirements.

*Government-funded plans are not eligible for patient support services that provide financial support through the programs. Patients receiving treatment or residing in MA or RI are not eligible for home infusion services. To receive home infusion support, patients must be referred to home infusion by their prescribing physician.

The dedicated *Chiesi Total Care Team* is made up of:

Pharmacists | Patient Service Coordinators | Reimbursement support | Nursing support

Lamzede Offerings



Infusion assistance[†]

- Chiesi Total Care may help patients understand their medication and the infusion process, and coordinate a suitable infusion site if needed
- If you determine home infusion is right for your patient, Chiesi Total Care may be able to assist eligible patients with delivery of medication and infusion supplies needed

[†]Patients receiving treatment or residing in MA or RI are not eligible for infusion assistance. To receive home infusion support, patient must be referred to home infusion by their prescribing physician. Please refer to the full [Terms and Conditions](#) for additional eligibility requirements.



Routine testing

- Healthcare providers should consider monitoring for the presence of serum oligosaccharides reduction and anti-drug antibodies in patients who demonstrate hypersensitivity reactions and should consider the risks and benefits of continued treatment in patients with serum oligosaccharides reduction and anti-Lamzede antibodies. There are no marketed tests for these antibodies against Lamzede. If monitoring is warranted, Chiesi Total Care may be able to help

Important Safety Information

The most common adverse reactions (incidence >20%) are hypersensitivity reactions including anaphylaxis, nasopharyngitis, pyrexia, headache, and arthralgia.

Please see complete Important Safety Information, including Boxed Warning, for Lamzede on back.



Phone

1-855-282-4883

Chiesi Total CareSM

Indication

Lamzede® (velmanase alfa-tycv) is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.

Important Safety Information

WARNING: SEVERE HYPERSENSITIVITY REACTIONS

Hypersensitivity Reactions Including Anaphylaxis

Patients treated with Lamzede have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during Lamzede administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue Lamzede immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to Lamzede may be considered.

Considerations Due to Hypersensitivity Reactions and/or Infusion-Associated Reactions (IARs)

Prior to Lamzede administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Inform patients and caregivers of the signs and symptoms of hypersensitivity reactions and IARs and instruct them to seek medical care immediately if such symptoms occur.

- If a severe hypersensitivity reaction (including anaphylaxis) or severe IAR occurs, immediately discontinue Lamzede administration and initiate appropriate medical treatment.
- In the event of a mild to moderate hypersensitivity reaction or a mild to moderate IAR, consider temporarily holding the infusion for 15 to 30 minutes, slowing the infusion rate to 25% to 50% of the recommended rate, and initiating appropriate medical treatment.

Hypersensitivity Reactions Including Anaphylaxis

Anaphylaxis and severe hypersensitivity signs and symptoms included cyanosis, hypotension, emesis, urticaria, erythema, facial swelling, pyrexia, and tremor.

Infusion-Associated Reactions (IARs)

The most frequent symptoms of IARs that occurred in >10% of the population were pyrexia, chills, erythema, vomiting, cough, urticaria, rash, and conjunctivitis.

Females of Reproductive Potential

Advise females of reproductive potential to use effective contraception during treatment and for 14 days after the last dose if Lamzede is discontinued. For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment with Lamzede.

Embryo-Fetal Toxicity

Based on findings from animal reproduction studies, Lamzede may cause embryo-fetal harm when administered to a pregnant female.

Common Adverse Reactions

The most common adverse reactions (incidence >20%) are hypersensitivity reactions including anaphylaxis, nasopharyngitis, pyrexia, headache, and arthralgia.

Please see accompanying [Full Prescribing Information](#) for Lamzede and full [Terms and Conditions](#) for additional Chiesi Total Care eligibility requirements.

Contact Information



Phone
1-855-282-4883



Website
chiesitotalcare.com



©Chiesi USA, Inc. 2023. All rights reserved.
Lamzede® is a registered trademark of CHIESI FARMACEUTICI S.p.A.
Chiesi Total CareSM is a service mark of CHIESI FARMACEUTICI S.p.A.
PP-VA-0142 V1.0

